Medifast, Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021; comparisons are with the same periods in 2020. Unless otherwise stated, amounts below are in U.S. dollars.
Business context
Medifast operates the OPTAVIA health and wellness business through a network of independent Coaches. About 91% of revenue came from subscription-based meal-plan orders, and product sales represented about 98% of revenue. The company reported 59,200 active earning OPTAVIA Coaches in Q2, up 62.2% year over year.
Financial results
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $394.2 million | $220.0 million | $734.9 million | $398.5 million |
| Gross profit | $293.7 million | $159.3 million | $542.3 million | $294.5 million |
| Operating income | $61.4 million | $28.1 million | $114.2 million | $51.6 million |
| Net income | $47.0 million | $21.9 million | $88.0 million | $40.4 million |
| Diluted EPS | $3.96 | $1.86 | $7.42 | $3.42 |
- Q2 revenue rose 79.2%; six-month revenue rose 84.4%. Management attributed growth primarily to more active earning Coaches and increased Coach productivity, which brought more clients onto the Optimal Weight 5 & 1 Plan.
- Gross margin was 74.5% in Q2 versus 72.4% a year earlier; six-month gross margin was 73.8% versus 73.9%. Q2 improvement reflected promotional activity in Q2 2020 that did not recur.
- Operating margin was 15.6% in Q2 versus 12.8%, and 15.5% for the six months versus 13.0%. SG&A increased in dollars with sales, including higher Coach commissions, employee costs, IT consulting and card fees.
- Coach commissions were 43.7% of Q2 revenue, up from 41.8%; for the six months they were 43.4%, up from 41.7%.
Cash flow, liquidity and debt
- Six-month operating cash flow was $86.2 million, compared with $84.3 million. Higher net income was largely offset by working-capital movements, including a $42.4 million cash use from increased inventory.
- Investing activities used $7.1 million, including $12.2 million of capital expenditures, principally to expand technology and supply-chain capabilities. Financing activities used $51.0 million, including $30.1 million of dividends paid and $19.7 million of stock repurchases.
- At June 30, cash and cash equivalents were $192.0 million and investment securities were $5.4 million; working capital was $150.3 million. Cash plus investment securities totaled $197.4 million.
- The company reported no borrowings under its $125 million secured revolving credit facility, which matures in April 2026 and includes up to $100 million of uncommitted incremental capacity. It was in compliance with covenants, including maximum net leverage of 3.00:1 and minimum interest coverage of 3.50:1.
- Lease obligations totaled about $20.5 million, including $5.0 million current. A quarterly dividend of $1.42 per share was declared for payment in Q3; management expects sufficient liquidity to continue the program but gave no assurance.
Changes, outlook and risks
- The Medifast-branded product line was fully sunset during Q2, consistent with the company’s brand strategy. Management cited related inventory write-offs, higher product and shipping costs, and increased use of co-manufacturers amid demand growth; the filing does not provide a clear amount for the write-offs.
- OPTA VIA products made up 94.1% of consumable units sold in Q2, compared with 83.0% a year earlier. The company’s average revenue per active earning Coach increased to $6,662 from $5,851.
- No specific full-year financial guidance is provided in the supplied filing text. Management described continued growth expectations but cautioned that results are not assured.
- COVID-19 had not meaningfully disrupted operations or the worldwide supply chain as of the filing, but variants, supplier or vendor disruptions, consumer behavior and the duration of the pandemic could affect results, cash flows and liquidity. The company said it continued to monitor inventory and supply-chain risks.
- Other risks include reliance on the Coach-based sales model, demand and Coach productivity, fulfillment and co-manufacturing costs, and the ability to sustain dividends. Ordinary-course litigation was not expected by management to have a material adverse effect, though outcomes cannot be predicted. No material changes to the risk factors in the 2020 Form 10-K were reported.
Key facts for investors to verify
- Whether rapid revenue growth and Coach productivity can be sustained, including client retention and subscription-order trends.
- Whether inventory growth, product availability, co-manufacturing and shipping costs affect cash conversion and margins.
- The financial and operational effects of ending the Medifast-branded line, including any remaining inventory or write-offs.
- Capital allocation: dividend capacity, repurchases, planned investment spending and compliance with credit-facility covenants.
- Potential COVID-related or other supply-chain disruption and any change in litigation or risk disclosures.